国: アイルランド
言語: 英語
ソース: HPRA (Health Products Regulatory Authority)
CEFIXIME
Sanofi-Aventis Ireland Limited T/A SANOFI
J01DD08
CEFIXIME
100 MG/5ml
Powder for Oral Suspension
Product subject to prescription which may not be renewed (A)
Third-generation cephalosporins
Authorised
1994-01-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Suprax 100mg/5ml Powder for Paediatric Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml dose of reconstituted suspension and each single dose sachet contains 100 mg cefixime. Excipients - contains sucrose 2.525g For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder for oral suspension When reconstituted with water gives a strawberry flavoured suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For use in the treatment of infections due to micro-organisms sensitive to the antibiotic including pathogens such as _Streptococci pneumoniae and pyogenes_,_ E.coli_, Proteus,_ H. influenza_ and_ B. catarrhalis_ (both beta lactamase positive and negative), Klebsiella and Enterobacter species. Most Enterococci, Staphylococci, Pseudomonas, Clostridia,_ Bacteroides fragili_s and_ Listeria monoyctogenes_ are resistant to Cefixime. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration is oral. ADULTS AND CHILDREN OF 12 YEARS AND OVER (OR MORE THAN 50KG BODY WEIGHT): The usual daily dose is 200-400mg in single or twice daily dosage regimen. In uncomplicated upper respiratory tract infections or urinary tract infections a daily dose of 200 mg may be sufficient. CHILDREN AGED 9 TO 12 YEARS: The usual total daily dose is 300mg (15ml of oral suspension) in single or twice daily regimen. CHILDREN AGED 5 TO 8 YEARS: The usual total daily dose is 200 mg (10ml of oral suspension) in single or twice daily dosage regimen. CHILDREN AGED 2 TO 4 YEARS: The usual total daily dose is 100 mg (5ml of oral suspension) in single or twice daily dosage regimen. CHILDREN AGED 6 MONTHS TO 2 YEARS: The usual total daily dose in 8 mg/kg in single or twice daily regimen. The safety and efficacy of use in infants less than 6 months of age has not been established. ELDERLY: The usual dosage is as for adults with appropriate modifications on the basis of renal impairment. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H 完全なドキュメントを読む